Provided by Tiger Trade Technology Pte. Ltd.

Invivyd, Inc.

0.9965
+0.04574.81%
Post-market: 0.9588-0.0377-3.78%19:57 EDT
Volume:5.43M
Turnover:5.19M
Market Cap:293.97M
PE:-2.74
High:1.03
Open:0.9450
Low:0.8664
Close:0.9508
52wk High:3.07
52wk Low:0.5031
Shares:295.00M
Float Shares:208.00M
Volume Ratio:0.99
T/O Rate:2.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3641
EPS(LYR):-0.3048
ROE:-95.89%
ROA:-45.67%
PB:1.62
PE(LYR):-3.27

Loading ...

Novabridge Biosciences Appoints DR. Srishti Gupta as Chief Executive Officer

THOMSON REUTERS
·
Jun 29

Invivyd posts CANOPY older-adult subgroup analysis presentation on pemivibart for COVID-19 prevention

Reuters
·
Jun 17

Invivyd completes enrollment of LIBERTY clinical trial

TIPRANKS
·
Jun 16

Invivyd's Late-Stage Trial of Covid Vaccine Alternative Completes Enrollment; Shares Rise Pre-Bell

MT Newswires Live
·
Jun 16

Invivyd - to Report Liberty Study Results in Q3 2026

THOMSON REUTERS
·
Jun 16

Invivyd Announces Completion of Enrollment in Phase 3 Liberty Trial Evaluating Vyd2311 Antibody Versus Mrna Covid-19 Vaccine

THOMSON REUTERS
·
Jun 16

Invivyd Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 15

Invivyd Price Target Maintained With a $10.00/Share by BTIG

Dow Jones
·
Jun 10

BRIEF-Invivyd - Expects Liberty Trial Topline Data In Q3 2026

Reuters
·
Jun 09

Invivyd doses first participants in Phase 3 LIBERTY trial of VYD2311 vs mRNA COVID vaccine

Reuters
·
Jun 09

Invivyd - Expects Liberty Trial Topline Data in Q3 2026

THOMSON REUTERS
·
Jun 09

Invivyd grants new hires options for 513,500 shares at $1.22 each under inducement plan

Reuters
·
Jun 03

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 03

Press Release: Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dow Jones
·
Jun 03

BRIEF-Invivyd Announces Completion Of Enrollment In Upsized Declaration Clinical Trial

Reuters
·
Jun 01

Invivyd completes enrollment in Phase 3 DECLARATION trial of VYD2311 for COVID prevention

Reuters
·
Jun 01

Invivyd Announces Completion of Enrollment in Upsized Declaration Clinical Trial, a Phase 3 Pivotal Study of Vyd2311, an Investigational Antibody to Prevent Covid

THOMSON REUTERS
·
Jun 01

Invivyd Price Target Maintained With a $10.00/Share by BTIG

Dow Jones
·
Jun 01

Invivyd to present at Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 27

Invivyd shareholders elect directors at annual meeting

Reuters
·
May 20